Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to $1.4 million.

  • Barinthus Biotherapeutics' Current Deferred Revenue fell 3140.9% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 3140.9%. This contributed to the annual value of $1.7 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Current Deferred Revenue stood at $1.4 million, which was down 3140.9% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Current Deferred Revenue peaked at $2.0 million during Q3 2024, and registered a low of $111000.0 during Q3 2022.
  • For the 4-year period, Barinthus Biotherapeutics' Current Deferred Revenue averaged around $842357.1, with its median value being $592500.0 (2021).
  • In the last 5 years, Barinthus Biotherapeutics' Current Deferred Revenue tumbled by 5317.92% in 2022 and then soared by 8176.4% in 2025.
  • Over the past 4 years, Barinthus Biotherapeutics' Current Deferred Revenue (Quarter) stood at $182000.0 in 2021, then plummeted by 39.01% to $111000.0 in 2022, then surged by 1465.77% to $1.7 million in 2024, then fell by 19.33% to $1.4 million in 2025.
  • Its Current Deferred Revenue was $1.4 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.5 million in Q1 2025.